Trusted Resources: News & Meetings
Latest announcements and gatherings
Gene Therapy for Sanfilippo: Where We Are Now
Gene therapy is a promising approach for a number of rare genetic diseases as it has the potential to treat the underlying cause. Here is more information about gene therapy, its challenges, and its current status as a treatment for Sanfilippo syndrome.
Sanfilippo syndrome is caused by mutations in genes that encode for enzymes which break down long chains of sugar molecules. The goal of gene therapy for Sanfilippo is to deliver correct copies of the faulty gene to patients so that their cells can produce functional enzymes to breakdown and prevent the accumulation of these sugar molecules.
The first is that each of the four subtypes of Sanfilippo syndrome is due to a mutation in a different gene, so each subtype requires a separate target for gene therapy. In other words, one gene therapy will not work for all Sanfilippo patients.
BookmarkRelated Content
-
Regenxbio Presents Positive Initial Data From Phase I/II Trial Of Rgx-111 for the Treatment of Severe MPS I at 18th ...REGENXBIO Inc. (Nasdaq: RGNX) today anno...
-
Treatment of Skeletal and Non-Skeletal Alterations of Mucopolysaccharidosis Type IVA by AAV-Mediated Gene TherapyMucopolysaccharidosis type IVA (MPSIVA) ...
-
EMA Grants Orphan Drug Designation to JR-171 for the Treatment of Mucopolysaccaridosis Type I (MPS I)JCR Pharmaceuticals Co., Ltd. announced ...
-
Mucopolysaccharidosis (MPS)https://slideplayer.com/slide/17257432/...
-
The Youngest Pair of Siblings With Mucopolysaccharidosis Type IVA to Receive Enzyme Replacement Therapy to Date: A C...Mucopolysaccharidosis type IVA (OMIM 253...
-
Cure Sanfilippo FoundationCure Sanfilippo Foundation is a Not-for-...
-
A Guide to Understanding MPS III (Sanfilippo Syndrome)MPS III belongs to a group of inherited ...
Powered by
